Details About Osteoarthritis

Definition

Osteoarthritis is a chronic, progressive degenerative disorder of synovial joints characterized by articular cartilage degradation, subchondral bone changes, osteophyte formation, and varying degrees of synovial inflammation, leading to pain, stiffness, and reduced joint function.

2. Causes / Risk Factors

A. Primary OA

Occurs without a specific underlying disease.

  • Increasing age
  • Genetic/hereditary factors
  • Female sex, particularly after menopause
  • Obesity
  • Repetitive joint use

B. Secondary OA

Occurs due to an identifiable cause:

  • Previous joint injury/trauma
  • Joint deformity
  • Congenital abnormalities
  • Rheumatoid arthritis or other inflammatory arthritis
  • Gout
  • Joint infection
  • Metabolic diseases
  • Previous surgery

Major risk factors

Age + obesity + previous joint injury + genetic predisposition + excessive mechanical stress






 

3. Clinical Manifestations

Major symptoms

  • Joint pain – usually worsens with activity/use and improves with rest.
  • Morning stiffness <30 minutes is typical.
  • Stiffness after prolonged inactivity ("gelling phenomenon").
  • Reduced range of motion.
  • Difficulty walking or performing daily activities.
  • Joint instability in advanced disease.

Signs

  • Bony enlargement of joints
  • Crepitus on movement
  • Joint-line tenderness
  • Reduced joint movement
  • Osteophyte formation
  • Usually little or no obvious warmth or swelling

Characteristic hand findings

  • Heberden's nodes → DIP joints
  • Bouchard's nodes → PIP joints
  • 1st CMC joint may also be affected.

Commonly affected joints

  • Knee
  • Hip
  • Hands
  • Spine
  • First MTP joint










4. Diagnosis

Diagnosis is mainly based on clinical findings + imaging.

A. Clinical examination

Look for:

  • Activity-related joint pain
  • Morning stiffness <30 min
  • Crepitus
  • Restricted movement
  • Bony enlargement

B. X-ray

Typical findings:

Joint-space narrowing + osteophytes + subchondral sclerosis + subchondral cysts

C. Laboratory tests

There is no specific blood test for OA.

Usually:

  • ESR → usually normal
  • CRP → usually normal
  • Rheumatoid factor → generally negative

Blood tests are mainly used to exclude other diseases such as rheumatoid arthritis or gout.

D. Synovial fluid

If joint aspiration is performed, OA typically shows non-inflammatory synovial fluid.

 

5. Pharmacotherapy

Treatment approach

Non-pharmacological therapy
↓
Topical NSAID
↓
Oral NSAID if required and appropriate
↓
Duloxetine / intra-articular corticosteroid in selected patients
↓
Surgery for severe refractory disease


6. Drugs: Indications, Contraindications & Adverse Effects

A. Paracetamol

Indication

  • Mild OA pain
  • When NSAIDs are contraindicated or not tolerated

Contraindication/caution

  • Severe hepatic impairment
  • Chronic heavy alcohol use

Adverse effects

  • Usually well tolerated at therapeutic doses
  • Hepatotoxicity in overdose or excessive chronic use

B. Topical NSAIDs

Examples: Diclofenac gel, ibuprofen gel

Indication

  • Mild–moderate localized OA, particularly knee and hand OA
  • Preferred when systemic NSAID risk is high

Contraindication/caution

  • NSAID hypersensitivity
  • Application over damaged/infected skin
  • Caution in patients with significant NSAID allergy

Adverse effects

  • Local skin irritation
  • Rash
  • Itching
  • Systemic NSAID effects are less common than with oral NSAIDs

 

C. Oral NSAIDs

Examples: Ibuprofen, naproxen, diclofenac

Indication

  • Moderate–severe OA pain
  • When topical treatment is inadequate

Contraindications/cautions

  • Active peptic ulcer/GI bleeding
  • Severe renal impairment
  • Severe heart failure
  • Significant cardiovascular disease
  • NSAID hypersensitivity
  • Avoid in the third trimester of pregnancy

Adverse effects

  • Gastritis
  • Peptic ulcer
  • GI bleeding
  • Renal impairment
  • Fluid retention/edema
  • Increased blood pressure
  • Cardiovascular events

Key point: Use the lowest effective dose for the shortest duration.

 

D. COX-2 selective NSAID

Example: Celecoxib

Indication

  • OA pain when an oral NSAID is required
  • May be preferred in some patients with increased GI risk

Contraindications/cautions

  • Sulfonamide/celecoxib hypersensitivity
  • Significant cardiovascular disease
  • Severe renal impairment
  • Pregnancy, particularly late pregnancy

Adverse effects

  • Dyspepsia
  • Edema
  • Hypertension
  • Renal impairment
  • Increased cardiovascular risk

 

E. Duloxetine

Indication

  • Chronic OA pain, particularly when pain persists despite conventional therapy.
  • Useful when NSAIDs are unsuitable or inadequate.

Contraindications/cautions

  • MAOI use
  • Severe hepatic impairment
  • Severe renal impairment
  • Caution with other serotonergic drugs

Adverse effects

  • Nausea
  • Dry mouth
  • Dizziness
  • Constipation
  • Insomnia
  • Increased sweating
  • Sexual dysfunction
  • Possible withdrawal symptoms if stopped abruptly

MOA:
SNRI → ↑ serotonin + norepinephrine → enhanced descending pain inhibition → ↓ pain

F. Intra-articular corticosteroid

Examples: Triamcinolone, methylprednisolone

Indication

  • Short-term relief of moderate–severe knee OA pain
  • Acute painful flare
  • When oral/topical medicines are inadequate

Contraindications

  • Joint infection
  • Infection at injection site
  • Uncontrolled systemic infection
  • Avoid inappropriate/repeated frequent injections

Adverse effects

  • Temporary increase in blood glucose
  • Post-injection pain
  • Infection, rarely
  • Skin atrophy/depigmentation
  • Repeated injections may have adverse effects on joint structures

G. Topical Capsaicin

Indication

  • Localized OA pain, especially knee/hand OA
  • Alternative or adjunct to other analgesics

Contraindication/caution

  • Broken or irritated skin
  • Hypersensitivity

Adverse effects

  • Burning sensation
  • Stinging
  • Redness
  • Skin irritation

MOA:
TRPV1 activation → reduced nociceptive signaling/substance P → decreased pain

                                                             
                                                           END OF THE DOCUMENT




 

Post a Comment

Previous Post Next Post